BOLD - Audentes Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BOLD is currently covered by 2 analysts with an average price target of $8.15. This is a potential upside of $6.98 (596.58%) from yesterday's end of day stock price of $1.17.

Audentes Therapeutics's activity chart (see below) currently has 27 price targets and 21 ratings on display. The stock rating distribution of BOLD is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 94.72% with an average time for these price targets to be met of 208 days.

Highest price target for BOLD is $10, Lowest price target is $3, average price target is $20.

Most recent stock forecast was given by DEBJIT CHATTOPADHYAY from GUGGENHEIM on 13-Dec-2024. First documented stock forecast 01-May-2017.

Currently out of the existing stock ratings of BOLD, 3 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$24

8 months 10 days ago
(13-Dec-2024)

7/8 (87.5%)

$13.99 (139.76%)

90

Buy

$20

$18.83 (1609.40%)

1 years 4 months 1 days ago
(22-Apr-2024)

9/10 (90%)

$9.99 (99.80%)

264

Buy

$48

5 years 8 months 19 days ago
(04-Dec-2019)

4/4 (100%)

$9.47 (24.58%)

224

Hold

$45

5 years 8 months 21 days ago
(03-Dec-2019)

4/4 (100%)

$8.67 (23.86%)

290

Hold

$57

5 years 8 months 21 days ago
(03-Dec-2019)

2/2 (100%)

$17.02 (43.32%)

468

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BOLD (Audentes Therapeutics) average time for price targets to be met?

On average it took 208 days on average for the stock forecasts to be realized with a an average price target met ratio 94.72

Which analyst has the current highest performing score on BOLD (Audentes Therapeutics) with a proven track record?

DAVID NIERENGARTEN

Which analyst has the current lower performing score on BOLD (Audentes Therapeutics) with a proven track record?

MOHIT BANSAL

Which analyst has the most public recommendations on BOLD (Audentes Therapeutics)?

David Nierengarten works at WEDBUSH and has 8 price targets and 5 ratings on BOLD

Which analyst is the currently most bullish on BOLD (Audentes Therapeutics)?

Christopher Raymond with highest potential upside - $18.83

Which analyst is the currently most reserved on BOLD (Audentes Therapeutics)?

Joshua Schimmer with lowest potential downside - -$19.97

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?